ALPS Medical Breakthroughs ETF (SBIO)
| Assets | $115.59M |
| Expense Ratio | 0.50% |
| PE Ratio | n/a |
| Shares Out | 3.13M |
| Dividend (ttm) | $0.07 |
| Dividend Yield | 0.19% |
| Ex-Dividend Date | Dec 21, 2023 |
| Payout Ratio | n/a |
| 1-Year Return | +45.36% |
| Volume | 15,906 |
| Open | 36.73 |
| Previous Close | 36.89 |
| Day's Range | 36.57 - 37.20 |
| 52-Week Low | 25.05 |
| 52-Week High | 42.73 |
| Beta | 0.87 |
| Holdings | 104 |
| Inception Date | Dec 31, 2014 |
About SBIO
Fund Home PageThe ALPS Medical Breakthroughs ETF (SBIO) is an exchange-traded fund that is based on the S-Network Medical Breakthroughs index. The fund tracks, a market-cap weighted index comprising US-listed biotech companies with one or more drugs currently in either Phase II or Phase III FDA clinical trials. SBIO was launched on Dec 31, 2014 and is issued by SS&C.
Top 10 Holdings
29.01% of assets| Name | Symbol | Weight |
|---|---|---|
| Corcept Therapeutics Incorporated | CORT | 3.84% |
| Krystal Biotech, Inc. | KRYS | 3.53% |
| Avidity Biosciences, Inc. | RNA | 3.38% |
| Arcellx, Inc. | ACLX | 3.19% |
| Alkermes plc | ALKS | 3.08% |
| Crinetics Pharmaceuticals, Inc. | CRNX | 2.97% |
| Immunovant, Inc. | IMVT | 2.53% |
| Denali Therapeutics Inc. | DNLI | 2.29% |
| Verona Pharma plc | VRNA | 2.12% |
| Agios Pharmaceuticals, Inc. | AGIO | 2.08% |
Dividends
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Dec 21, 2023 | $0.071 | Dec 27, 2023 |
| Dec 19, 2019 | $0.016 | Dec 27, 2019 |
| Dec 20, 2018 | $0.784 | Dec 27, 2018 |
| Dec 21, 2017 | $0.579 | Dec 28, 2017 |
News
Steady Rate Cuts Feed Surging Biotech ETF SBIO
Yet another rate cut has come and gone, and even with somewhat steady inflation reads, further cuts may be in the pipeline. Debt-heavy areas like tech stand to benefit, but for those already heavily e...
How Election Results Could Impact Biotech ETFs
Biotech stocks and ETFs are among the assets that responded positively to last week's presidential election results. As just one example, the ALPS Medical Breakthroughs ETF (SBIO) is up 10% for the we...
Biotech ETF SBIO Laps Tech Rivals Over 1 Year
If there were a defining sector for investors this year, it has been tech investing. The ascendance of AI has lifted valuations and investor portfolios, boosting the market as a whole.
Advacam & Vector Space Biosciences sign Letter of Intent (LOI) to Develop AI Models & CubeSat Payloads for the Space Industry
LA JOLLA, Calif.--(BUSINESS WIRE)---- $SBIO #Advacam--Advacam, provider of radiation detectors that map radiation aboard the International Space Station (ISS) and Vector Space Biosciences (crypto symb...
Tailwinds Emerging for This Biotech ETF
The effects of the Federal Reserve's recent interest rate cut haven't fully been felt by the economy or financial markets. But the first instance of U.S. monetary easing in over four years may be a bo...
Vector Space Biosciences (SBIO) Is Now Available for Trading on LBank Exchange
Road Town, Virgin Islands--(Newsfile Corp. - September 24, 2023) - LBank Exchange, a global digital asset trading platform, listed Vector Space Biosciences (SBIO) on September 15, 2023. For all users ...
